Mar 18, 2019 7:30 am EDT Nemus Bioscience Reports Nanoemulsion of NB1111 Superior to First-Line Therapy, Latanoprost, in Lowering Intraocular Pressure in Validated Normotensive Animal Model Testing
Mar 12, 2019 7:30 am EDT Nemus Bioscience Confirms NB1111 Mechanism of Action and Reports Positive Results from Glaucoma Biomarker Studies in Human Donor Tissues
Mar 4, 2019 7:30 am EST Nemus Bioscience Signs Agreement with Noramco to Manufacture Proprietary Cannabidiol Analog
Feb 14, 2019 7:00 am EST Nemus Bioscience Signs Agreement with Pharmaceuticals International Inc. to Develop Dosage Formulation for Human Dosing with NB1111 for Glaucoma
Jan 23, 2019 7:30 am EST Nemus Bioscience to Present at the NobleCon XV and 8th Annual Glaucoma 360 New Horizons Forum
Jan 3, 2019 7:00 am EST Nemus Bioscience to Present at the 2nd Annual Sach’s Neuroscience Innovation Forum and Biotech Showcase 2019
Nov 29, 2018 3:51 pm EST Nemus Bioscience to Present at Investment and Scientific Conferences in December